Cara Therapeutics reported $132.67M in Current Assets for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 735M 11M
Aerie Pharmaceuticals AERI:US $ 313M 25M
Antares Pharma ATRS:US $ 115M 3M
Biodelivery Sciences International BDSI:US $ 159.01M 25.68M
Chugai Pharma 4519:JP Y 742331M 46719M
Depomed DEPO:US $ 104.49M 30.97M
Endo International Ordinary Shares ENDP:US $ 2802.82M 116.68M
Halozyme Therapeutics HALO:US $ 500.36M 32.39M
Horizon Pharma HZNP:US $ 2732.32M 1243.23M
JAZZ PHA JAZZ:US $ 2555.57M 253.23M
Johnson & Johnson JNJ:US $ 57578M 11686M
Neurocrine Biosciences NBIX:US $ 1146M 178M
Pacira Pharmaceuticals PCRX:US $ 455.82M 24.23M
Pfizer PFE:US $ 46424M 11686M
Redhill Biopharma RDHL:US $ 56.95M 4.18M
Revance Therapeutics RVNC:US $ 502.77M 15.67M
Teva Pharmaceutical Industries TEVA:US $ 12160M 621M
Vanda Pharmaceuticals VNDA:US $ 380.86M 20.11M